Jon CohenScience's COVID-19 reporting is supported by the Heising-Simons Foundation.Another COVID-19 vaccine has run into trouble in South Africa, showing less protection there than elsewhere because a SARS-CoV-2 variant that can apparently dodge key antibodies has become widespread.
In the wake of the new finding, the country, which had pinned its pandemic hopes on this particular vaccine, halted an immunization campaign launched only last week.The stakes are high for the vaccine globally because its makers, AstraZeneca and the University of Oxford, hope it will be widely used in developing countries; they project they can produce 3 billion doses this year for around $3 each, far more product at a far less lower price than any other.